There is increasing use of head-to-head clinical trials in dermatology when establishing the efficacy of a new treatment.
Introduction
Clinical trials may include the use of placebo (PBO), active treatment (an approved therapy, standard care or the best available intervention) or no control group. 1 Active-controlled clinical trials (ACTs) are increasingly the benchmark in many fields of medicine when establishing the efficacy of a new treatment. 2, 3 Even if ACTs do not achieve the desired primary outcomes or prove the hypothesis, negative results still provide highly valuable information 4 by identifying subpopulations who may stand to gain the most benefits and ascertain those in whom the drug should be avoided. Prior to the 2000s, ACTs were quite uncommon for systemic agents in moderate-to-severe psoriasis. For example, a systematic review of dermatological studies from 1977 to 2000 found only 31 (12.5%) randomized controlled trials (RCTs) comparing treatment modalities in different therapeutic classes. 5 Although placebo-controlled trials often precede active-controlled trials in psoriasis research, head-tohead comparisons for new therapies are becoming the rule rather than the exception. 6 Preference for ACTs may be attributed to the pragmatic nature of such trials as they assess the comparative values of different treatments as opposed to choosing to treat or not (i.e. PBO). However, head-to-head clinical trials present unique challenges in the design and the interpretation of results. Active-controlled clinical trials methodology can be classified into different types of comparisons: non-inferiority trials (which aims to demonstrate a minimum level of efficacy in the investigational intervention vs. the comparator by a prespecified amount); equivalence trials (often employed in biosimilar studies to evaluate whether the investigational intervention is comparable enough, or not 'too different', to the originator drug); and superiority trials 7 (the most convincing way to determine whether the investigational intervention is more efficacious than the comparator; Fig. 1 ). 8, 9 It is critical to understand the type of (1) Experimental is superior to active control. The CI does not include zero treatment difference. (2) Experimental is superior to active control, but it has a wider CI than in (1) , meaning that the estimate of the difference between treatments is less precise (due to more variance or a smaller sample size). (3) There is no difference between treatments. (4) The entire CI lies below the line of D0, favouring active control. (b) Noninferiority Clinical Trial Principles illustrated by different scenarios (1) (2) (3) (4) (5) (6) , where the effects of an active control and experimental treatment are within the confidence intervals (along the x-axis).
(1) Experimental is non-inferior to control but not significantly different from active control. (2) Experimental is non-inferior to control but is significantly different from control. (3) Experimental is somewhat inferior to control. Experimental is not inferior because the CI does not include the non-inferior margin or the line of D0. (4) Inconclusive because the CI includes values on both sides of the non-inferiority margin and the line of no treatment difference (D0). (6) Experimental is inferior to control because it includes the non-inferiority margin. (7) Experimental is inferior to control and is more certain of its inferiority as compared to scenario (5) because it does not include the non-inferiority margin. (c) Equivalence Clinical Trial Principles illustrated by different scenarios (1) (2) (3) (4) (5) , where the effects of an active control and experimental treatment are within the confidence intervals (along the x-axis comparison as the design directly impacts the conclusions that can be drawn from the results. Particularly, it is crucial that the margins or delta of comparison, also known as the clinically acceptable maximum difference between two treatments, be well defined and justified as this difference directly influences sample size estimates as well as study conclusions.
We recently conducted a systematic review of active-controlled trials of biosimilars and found that five of the nine studies did not report adequate information to ascertain key aspects of study design, which led us to conduct a larger systematic review inclusive of all systemic and biologic ACTs in psoriasis. 10 Given the increasing use of active controls, development of new investigative therapies and implications for evidence-based practice, we sought to determine the range of statistical parameters for active-controlled systemic and biologic therapeutic trials in psoriasis. The objective of this study was to summarize the different types of ACTs (superiority, NI or equivalence trials) and to synthesize current evidence to inform future comparative trials in psoriasis.
Methods
We conducted a systematic search based on the Cochrane Handbook for Systematic Reviews of Interventions guidelines using MEDLINE, Scopus, EMBASE, Cochrane Central Register of Controlled Trials, LILACS, Web of Science and ClinicalTrials.-gov from inception to 31 August 2017 11 to identify eligible articles using relevant keywords and Medical Subject Headings with the assistance of a professional librarian (Table S1 ). To avoid possible publication bias and identify ongoing or unpublished trials, we also searched clinicaltrialresults.org, World Health Organization International Clinical Trials Registry Platform and Food and Drug Administration websites on 7 September 2017. To obtain data from unpublished studies and abstracts, we contacted corresponding authors or industry sponsors. Supplementary data were retrieved if the full-text publications did not contain data points of interest. Our inclusion criteria (Table S2) included adult patients (≥18 years old) with plaque psoriasis (PsO) randomized to receive monotherapy of an experimental intervention or active control. Our outcome of interest was the Psoriasis Area and Severity Index (PASI) score, as this is the measure typically used in clinical trials to define successful treatment, 12 measured at week 12 or later.
Study selection
Study selection was carried out according to the PRISMA statement (Fig. 2) . 13 Two reviewers (MTW and JA) independently reviewed the titles and abstracts of all studies for inclusion and exclusion criteria, which had been downloaded from the search into EndNote X7.7.1 (Thomson Reuters, Pennsylvania, USA). EndNote X7.7.1 and STATA 13.1 (StataCorp, College Station, TX, USA) were used to identify duplicates. Titles and abstracts were screened for inclusions, followed by full-text retrieval if abstracts were insufficient to determine whether studies met inclusion and exclusion criteria. In cases of disagreements, the two reviewers (MTW and JA) compared findings and reached consensus about eligibility and on classification. If consensus was not reached, a third reviewer (EDD) was consulted. Singlecentre studies were excluded as small sample sizes typically yield studies that are inadequately powered. Although our search criteria included phototherapy, we excluded phototherapies after the database search in addition to topical treatments as PsO RCTs generally examine oral and biologic therapies.
Data extraction and management
Two authors (MTW and JA) independently extracted predetermined data from all 49 RCTs that met inclusion criteria. RCTs were classified into superiority, NI or equivalent trial design based on the language used in the publications and the reported statistical parameters between the experimental and active control groups. ACTs were deemed as 'other head-to-head comparisons' if the authors could not retrieve adequate information to classify the RCTs as one of the three aforementioned study designs. For the purpose of this manuscript, ACTs were classified according to the type of comparison of the investigative drug vs. the active control (i.e. a study was considered as a NI ACT if any of the hypotheses tested non-inferiority of an investigative intervention vs. active control, even if it also explored superiority to placebo). For studies with multiple hypotheses tested, ACTs were classified according to whichever hypothesis was tested first sequentially. We abstracted the following data: study design, sample size, power, confidence intervals, margin or delta, primary outcome and response rates (Tables 1-4) . From the extracted data, we summarized ranges for continuous data and calculated proportions and percentages for categorical data. Studies with missing values were excluded from specific analyses. Statistical analyses were performed using STATA 13.1.
Risk of bias
Often, systematic reviews include an assessment of the risk of bias, which involves rating each RCT on several domains such as randomization, blinding and missing data. 14, 15 However, a formal risk of bias assessment was not applicable to our study outcome as we focused on specific details in statistical analyses and publication.
Results
We identified 49 psoriasis RCTs for oral and biologic therapies with active comparators. Most were phase 3 trials; however, there was one phase 2 trial 16 and four RCTs 17-20 that did not specify the trial phase. Of the 49 ACTs, there were 13 superiority studies (Table 1) , eight non-inferiority studies (Table 2) , seven equivalence trials (Table 3 ) and 21 'other head-to-head' comparisons ( Table 4 ) that could not be classified into one of these three categories based on our methodology. The 'other head-to-head' studies did not use appropriate wording or statistical parameters necessary to ascertain the a priori design of the trial. We were also unable to obtain this information after requests to the study sponsors and corresponding authors. Of particular interest is the ambiguous reporting of margins or delta, as this directly impacts the interpretation of results. Of the 49 studies, one of 13 (0.08%), eight of eight (100%) and six of seven (85.17%) of the superiority, NI and equivalence trials, respectively, reported the margin explicitly (i.e. the reader did not have to perform power analyses or calculations to derive missing information). However, in five of the superiority trials, we were able to manually calculate the delta (otherwise known as the effect size or acceptable treatment difference).
Our findings indicate that the acceptable difference between treatment arms range from 14% to 20% for superiority trials for PASI75, PASI90 or PASI100 endpoints. The NI studies reported lower bound margins ranging from À20% to À10% for PASI75 or PASI90 endpoints. The equivalence trials reported upper and lower margins ranging from AE12.5% to AE18% for PASI75 or PASI change (mean or per cent) from baseline endpoints. Of which, one equivalence RCT reported AE5 points in the mean PASI score. None of the 'other head-to-head' trials reported margins or acceptable differences between treatment arms.
Discussion
This systematic review demonstrated considerable heterogeneity in the conduct of head-to-head dermatology trials, reflective of underlying variations in protocol parameters. Although several regulatory bodies have provided lengthy guidance documents for head-to-head trial design [21] [22] [23] and reporting, 24, 25 our results revealed discrepancies in the conduct and reporting of ACTs in dermatology. Regarding study conduct, there was a diverse range of acceptable treatment differences and inconsistency in the choice of statistical analyses. Inconsistency in the choice of A systematic review of psoriasis active comparator trials statistical analyses is not problematic per se, as this should be dictated by the primary study question (i.e. establishing noninferiority, equivalence or superiority). More problematic, however, is variation in clinical trials reporting. For example, there were a high proportion of studies that omitted data, had ambiguity in power analyses and violated guidelines for good reporting. 24 Indeed, only one of the eight NI trials successfully indicated non-inferiority study design in the title of the manuscript -the first component of the CONSORT guidelines. Our findings indicate a lack of standardization in study design and reporting, which is critical to allow for appropriate comparison and interpretation of results. Clinical trials study design and reporting are fundamental because even the slightest change in any study parameters could result in entirely different study conclusions and determination of treatment efficacy. Studies used language implying either superiority (such as 'superior to'), non-inferiority or equivalence RCT design but had much variation in the margins and choice of analyses. Designing ACTs requires a delicate balance of utilizing parameters from current literature and expertise from clinical and research specialists to determine clinically acceptable measures, otherwise known as the margin of error or delta in clinical trials. Our review found a wide range of acceptable treatment differences in superiority, non-inferiority and equivalence trials (range: 14 to 20%, À20% to À10% and AE12.5% to AE18%, respectively). Interpretation and application of the margin or delta influence clinical decision-making as healthcare providers and patients may differ in their opinions of the maximum acceptable difference between interventions. For example, if the true PASI90 response rates were 60% for an active control and 50% for an investigative treatment, this would be considered as sufficiently similar responses in an equivalence study with AE10% margins. Although one healthcare professional may consider this to be sufficiently 'equal' and comfortably prescribe the investigative drug as a replacement, another physician might require more conservative margins.
Readers should also be made aware that the choice of statistical analyses can bias study conclusions. For superiority trials, the intention-to-treat analyses imply a conservative effect on the outcome of the trial. However, for non-inferiority and equivalence trials, ITT analyses do not have the same conservative effect, and it is unclear whether per-protocol analyses have a conservative effect. Therefore, it is recommended to conduct both intention-to-treat (full analysis set) and 'as treated' (perprotocol) analyses to support research findings. 26 Without both analyses supporting study conclusions in NI and equivalence trials, readers should be cautious of the comparative efficacy conclusions. Only 28.57% (2/7) of the completed NI dermatology trials performed both intention-to-treat and per-protocol analyses, which is comparatively worse than another systematic review inclusive of other fields of medicine, which found 44% of NI trials conducting both analyses. 27 Of the three full-text A closed-testing procedure used to evaluate different hypotheses. The non-inferiority testing was followed by superiority testing between experimental and placebo. ¶Firstly evaluated non-inferiority and secondly evaluated superiority of ixekizumab to ustekinumab, as measured by the proportion of patients achieving a PASI 90 response at week 12. † †Study power was not identified for non-inferiority, only for superiority as >0.93 and therefore may result in an underpowered study for testing non-inferiority. This study was classified as non-inferiority because the non-inferiority hypothesis was required to be satisfied prior to superiority testing. The italicized numbers are the observed data, instead of the expected response rates and sample size required for power analyses decided a priori. ADA, adalimumab; BID, bidaily; BIW, biweekly; CI, confidence interval; ETA, etanercept; ITT, intention to treat; IXE, ixekizumab; MTX, methotrexate; NR, not reported; OD, once daily; PBO, placebo; PP, per protocol; Q2W, every 2 weeks; Q4W, every 4 weeks; Q6W, every 6 weeks; SC, subcutaneous; SEC, secukinumab; UA, unavailable data point; UST, ustekinumab. A systematic review of psoriasis active comparator trials Table 4 Head-to-head research trials that could not be classified as any of the aforementioned three statistical designs. A systematic review of psoriasis active comparator trials manuscripts for equivalence trials, only one performed both ITT and per-protocol analyses. This demonstrates a lack of handling of missing data using more modern and statistically valid approaches. In addition to the above, details of power analyses and margin rationale were omitted and inconsistent, 25 further complicating interpretation of study findings. The International Committee of Medical Journal Editors states that statistical methods should be described with 'enough detail to enable a knowledgeable leader with access to the original data to verify the reported results'. 28 However, only seven of the 13 superiority trials reported all of the necessary information to calculate the hypothesized difference between treatments. Of these, only one trial explicitly stated the difference of treatment effect 29 whereas we, the authors, used the reported statistical parameters to find this 'acceptable difference' for the other trials. In our review, the non-inferiority margin was explicitly stated in all of the trials (8/8, 100%), which is similar to previous findings from Rehal et al. 30 reporting 98%
(164/168) margin specification. Six of seven equivalent studies (85.71%) reported the margins, which is comparable to another study quoting 36 of 42 (86.00%). 27 Critically, there was a lack of transparency as we could not make definitive conclusions about 21 trials (classified as 'other head-to-head comparisons') due to missing data. Although a high proportion of these are ongoing or unpublished, the lack of transparency should not be minimized as these parameters are typically decided a priori. Margin rationale can involve utilizing historical data and clinical judgement as recommended by the International Conference on Harmonisation. 23 However, our findings for psoriasis ACT margin justification are comparatively worse than other fields of medicine. For example, a recent systematic review of NI trials indicated that less than half of the publications reported clinical or statistical justification for the margin of error. 30 In our review, two of the eight (25.0%) NI trials and only one of the equivalence trials (1/7, 14.29%) presented reason for margin selection as opposed to 48% (80/162) and 50% (21/42), respectively.
27
Our findings are similar to other studies that reviewed margin specification but in other aspects lacked compliance with study conduct and methodology reporting.
As with all studies, our systematic review has limitations. Our results should be approached with caution as there were relatively fewer studies to derive conclusions from (as compared to other fields of medicine). Furthermore, restricting medications to only oral and biologic therapies may have limited our study findings. Lastly, we did not conduct a formal meta-estimate. Typically, meta-analyses utilize observed response rates to estimate the effect of treatment size. However, in this case, it would be inappropriate to conduct a formal meta-analysis based on arbitrarily determined numbers (by clinical triallists) and pooling such findings may not lead to more certain outcomes. 31 Finally, we were unable to obtain information as described above despite repeated efforts to contact sponsors.
Our findings show incongruity in ACT conduct and reporting, which is required for proper evaluation of research findings. Clinicians should be made aware of the different types of study design and of varying acceptable treatment differences, from which conclusions are derived. Readers should be wary of studies that do not report necessary data to reproduce information that is required to determine acceptable differences. Although treatment differences utilized in clinical trials depend upon clinical expertise, there is currently no clear consensus of acceptable treatment differences for ACTs in psoriasis. The lack of agreement makes it difficult to interpret and apply ACT results. We recommend publishing an international consensus statement for various dermatological comparative study designs that include multiple-arm clinical trials (i.e. experimental, active control and placebo) and suggestions of clinically acceptable differences between treatment options. In the meantime, we strongly urge authors to explicitly state study parameters and communicate consistently per the CONSORT statement for RCT reporting. Lastly, we suggest that sponsors may want to participate by increasing transparency and openly reporting study parameters that are decided a priori.
Conclusion
Considering the impact of these trials on evidence-based medicine, it is imperative for clinicians to understand the variety of statistical measures to interpret research findings appropriately. Treatment differences that appear to be acceptable to clinical trials range from 14% to 20% for superiority, À20% to À12% for non-inferiority and AE12.5% to AE18% for equivalence active comparator trials. The results demonstrate the need for standardized ACT design and clarity in reporting clinical research findings. A better understanding of identifying acceptable margins in the field of dermatology may help future comparison study design.
